Avalo's Phase 2 data lifts shares 45% as skin drug shows 42% response in hidradenitis suppurativa

Avalo Therapeutics reported that its experimental therapy abdakibart met the primary goal of a Phase 2 trial in patients with hidradenitis suppurativa. Both low and high dose groups achieved response rates of roughly 42%, which was about 17 percentage points higher than the placebo arm.

The positive outcome prompted a sharp rise in Avalo's stock, jumping about 45% after the announcement. The company also secured a $375 million financing round and indicated plans to advance the drug toward later‑stage development.

Analysts noted that despite recent placebo‑response challenges at competing firms, Avalo's results were comparable to the performance of UCB’s marketed product Bimzelx, suggesting the candidate could become a viable alternative in this difficult‑to‑treat condition.